Filing Details
- Accession Number:
- 0001437749-25-020518
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-16 16:56:08
- Reporting Period:
- 2025-06-12
- Filing Date:
- 2025-06-16
- Accepted Time:
- 2025-06-16 16:56:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1710340 | Eton Pharmaceuticals Inc. | ETON | Pharmaceutical Preparations (2834) | 371858472 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1968254 | David Krempa | C/O Eton Pharmaceuticals, Inc. 21925 W. Field Parkway, Suite 235 Deerpark IL 60010-7208 | Chief Business Officer | No | Yes | No | No |
Transaction Summary
Sold: | 34,000 shares | Avg. Price: $14.83 | Total Value: $504,317.63 |
Number of Shares After Transactions: | 612,646 shares |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2025-06-12 | 16,977 | $14.92 | 629,669 | No | 4 | S | Direct | |
Common Stock | Disposition | 2025-06-13 | 6,800 | $14.77 | 622,869 | No | 4 | S | Direct | |
Common Stock | Disposition | 2025-06-16 | 10,223 | $14.73 | 612,646 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The shares were sold in multiple trades at prices ranging from $14.77 to $14.98. The price reported above reflects the weighted average sales price.
- The shares were sold in multiple trades at prices ranging from $14.75 to $14.81. The price reported above reflects the weighted average sales price.
- The shares were sold in multiple trades at prices ranging from $14.50 to $14.79. The price reported above reflects the weighted average sales price.
- The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.